Abstract | BACKGROUND AND PURPOSE: METHODS: Fifty FRDA patients were randomly divided into high or low dose CoQ(10)/ vitamin E groups. The change in International Co-operative Ataxia Ratings Scale (ICARS) was assessed over 2 years as the primary end-point. A post hoc analysis was made using cross-sectional data. RESULTS: At baseline serum CoQ(10) and vitamin E levels were significantly decreased in the FRDA patients (P < 0.001). During the trial CoQ(10) and vitamin E levels significantly increased in both groups (P < 0.01). The primary and secondary end-points were not significantly different between the therapy groups. When compared to cross-sectional data 49% of all patients demonstrated improved ICARS scores. This responder group had significantly lower baseline serum CoQ(10) levels. CONCLUSIONS:
|
Authors | J M Cooper, L V P Korlipara, P E Hart, J L Bradley, A H V Schapira |
Journal | European journal of neurology
(Eur J Neurol)
Vol. 15
Issue 12
Pg. 1371-9
(Dec 2008)
ISSN: 1468-1331 [Electronic] England |
PMID | 19049556
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antioxidants
- Electron Transport Chain Complex Proteins
- Ubiquinone
- Vitamin E
- coenzyme Q10
|
Topics |
- Adolescent
- Adult
- Antioxidants
(administration & dosage)
- Dose-Response Relationship, Drug
- Electron Transport Chain Complex Proteins
(genetics, metabolism)
- Endpoint Determination
- Energy Metabolism
(drug effects, physiology)
- Female
- Friedreich Ataxia
(drug therapy, metabolism, physiopathology)
- Humans
- Male
- Mitochondria
(genetics, metabolism)
- Muscle, Striated
(metabolism, physiopathology)
- Oxidative Stress
(drug effects, physiology)
- Predictive Value of Tests
- Treatment Outcome
- Ubiquinone
(administration & dosage, analogs & derivatives, blood, deficiency)
- Up-Regulation
(drug effects, physiology)
- Vitamin E
(administration & dosage)
- Vitamin E Deficiency
(blood, drug therapy, physiopathology)
- Young Adult
|